A Post Hoc Analysis of Efficacy Data on Sarecycline in Hispanics with Acne from Two Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trials
Sarecycline is a novel, narrow-spectrum, third generation tetracycline class antibiotic approved by the Food and Drug Administration (FDA) for the treatment of moderate-to-severe acne in patients ages nine and older. Recently, focus has increased on whether treatment responses differ in acne in skin...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Antibiotics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-6382/12/1/89 |
| _version_ | 1797446995410944000 |
|---|---|
| author | Angela Yen Moore Kara Hurley Stephen Andrew Moore |
| author_facet | Angela Yen Moore Kara Hurley Stephen Andrew Moore |
| author_sort | Angela Yen Moore |
| collection | DOAJ |
| description | Sarecycline is a novel, narrow-spectrum, third generation tetracycline class antibiotic approved by the Food and Drug Administration (FDA) for the treatment of moderate-to-severe acne in patients ages nine and older. Recently, focus has increased on whether treatment responses differ in acne in skin of color. Here, we aimed to analyze the efficacy of using sarecycline in Hispanics. We report pooled post hoc analysis of efficacy data on sarecycline in Hispanics with acne from two phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trials, SC1401 and SC1402. Of 2002 patients in the pooled trials with moderate-to-severe acne, 26.9% were Hispanic. Facial inflammatory lesion counts decreased as early as week 3 by 26% (<i>p</i> = 0.0279), with continued reduction by 41% by week 6 (<i>p</i> = 0.0003), by 51% by week 9 (<i>p</i> < 0.0001), and by 55% by week 12 (<i>p</i> < 0.0001). Acne is the most common skin condition diagnosed in Hispanics, and this study illustrates a statistically significant reduction in acne in Hispanic patients with moderate-to-severe acne treated with oral sarecycline. Therefore, oral sarecycline shows promising results as a safe and effective treatment for acne in Hispanics. |
| first_indexed | 2024-03-09T13:48:29Z |
| format | Article |
| id | doaj.art-cd0d2a0e036844748b7e9de164457f8e |
| institution | Directory Open Access Journal |
| issn | 2079-6382 |
| language | English |
| last_indexed | 2024-03-09T13:48:29Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibiotics |
| spelling | doaj.art-cd0d2a0e036844748b7e9de164457f8e2023-11-30T20:55:33ZengMDPI AGAntibiotics2079-63822023-01-011218910.3390/antibiotics12010089A Post Hoc Analysis of Efficacy Data on Sarecycline in Hispanics with Acne from Two Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical TrialsAngela Yen Moore0Kara Hurley1Stephen Andrew Moore2Arlington Center for Dermatology, Arlington, TX 76011, USATexas College of Osteopathic Medicine, University of North Texas Health Science Center, Fort Worth, TX 76107, USAArlington Center for Dermatology, Arlington, TX 76011, USASarecycline is a novel, narrow-spectrum, third generation tetracycline class antibiotic approved by the Food and Drug Administration (FDA) for the treatment of moderate-to-severe acne in patients ages nine and older. Recently, focus has increased on whether treatment responses differ in acne in skin of color. Here, we aimed to analyze the efficacy of using sarecycline in Hispanics. We report pooled post hoc analysis of efficacy data on sarecycline in Hispanics with acne from two phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trials, SC1401 and SC1402. Of 2002 patients in the pooled trials with moderate-to-severe acne, 26.9% were Hispanic. Facial inflammatory lesion counts decreased as early as week 3 by 26% (<i>p</i> = 0.0279), with continued reduction by 41% by week 6 (<i>p</i> = 0.0003), by 51% by week 9 (<i>p</i> < 0.0001), and by 55% by week 12 (<i>p</i> < 0.0001). Acne is the most common skin condition diagnosed in Hispanics, and this study illustrates a statistically significant reduction in acne in Hispanic patients with moderate-to-severe acne treated with oral sarecycline. Therefore, oral sarecycline shows promising results as a safe and effective treatment for acne in Hispanics.https://www.mdpi.com/2079-6382/12/1/89acne vulgarisskin colortetracyclinesarecyclineHispanic |
| spellingShingle | Angela Yen Moore Kara Hurley Stephen Andrew Moore A Post Hoc Analysis of Efficacy Data on Sarecycline in Hispanics with Acne from Two Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trials Antibiotics acne vulgaris skin color tetracycline sarecycline Hispanic |
| title | A Post Hoc Analysis of Efficacy Data on Sarecycline in Hispanics with Acne from Two Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trials |
| title_full | A Post Hoc Analysis of Efficacy Data on Sarecycline in Hispanics with Acne from Two Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trials |
| title_fullStr | A Post Hoc Analysis of Efficacy Data on Sarecycline in Hispanics with Acne from Two Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trials |
| title_full_unstemmed | A Post Hoc Analysis of Efficacy Data on Sarecycline in Hispanics with Acne from Two Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trials |
| title_short | A Post Hoc Analysis of Efficacy Data on Sarecycline in Hispanics with Acne from Two Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trials |
| title_sort | post hoc analysis of efficacy data on sarecycline in hispanics with acne from two phase 3 multicenter randomized double blind placebo controlled clinical trials |
| topic | acne vulgaris skin color tetracycline sarecycline Hispanic |
| url | https://www.mdpi.com/2079-6382/12/1/89 |
| work_keys_str_mv | AT angelayenmoore aposthocanalysisofefficacydataonsarecyclineinhispanicswithacnefromtwophase3multicenterrandomizeddoubleblindplacebocontrolledclinicaltrials AT karahurley aposthocanalysisofefficacydataonsarecyclineinhispanicswithacnefromtwophase3multicenterrandomizeddoubleblindplacebocontrolledclinicaltrials AT stephenandrewmoore aposthocanalysisofefficacydataonsarecyclineinhispanicswithacnefromtwophase3multicenterrandomizeddoubleblindplacebocontrolledclinicaltrials AT angelayenmoore posthocanalysisofefficacydataonsarecyclineinhispanicswithacnefromtwophase3multicenterrandomizeddoubleblindplacebocontrolledclinicaltrials AT karahurley posthocanalysisofefficacydataonsarecyclineinhispanicswithacnefromtwophase3multicenterrandomizeddoubleblindplacebocontrolledclinicaltrials AT stephenandrewmoore posthocanalysisofefficacydataonsarecyclineinhispanicswithacnefromtwophase3multicenterrandomizeddoubleblindplacebocontrolledclinicaltrials |